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Huntington’s disease (HD) is caused by a CAG ex-
pansion in the huntingtin gene. Expansion of the
polyglutamine tract in the huntingtin protein results
in massive cell death in the striatum of HD patients.
We report that human induced pluripotent stem cells
(iPSCs) derived from HD patient fibroblasts can be
corrected by the replacement of the expanded CAG
repeat with a normal repeat using homologous re-
combination, and that the correction persists in
iPSC differentiation into DARPP-32-positive neurons
in vitro and in vivo. Further, correction of the HD-
iPSCs normalized pathogenic HD signaling path-
ways (cadherin, TGF-b, BDNF, and caspase activa-
tion) and reversed disease phenotypes such as
susceptibility to cell death and altered mitochondrial
bioenergetics in neural stem cells. The ability tomake
patient-specific, genetically corrected iPSCs from
HD patients will provide relevant disease models in
identical genetic backgrounds and is a critical step
for the eventual use of these cells in cell replacement
therapy.
INTRODUCTION
Huntington’s disease (HD) is a progressive autosomal dominant
neurodegenerative disorder caused by an expansion of poly-
glutamine (CAG) repeats in the huntingtin (HTT) protein.
HD patients have progressive motor dysfunction, cognitive
decline, and psychological problems. The age of onset for these
symptoms is directly correlated with the number of repeats,
where more than 36 repeats is considered a pathological
threshold. With no effective disease modifying therapies yet
developed for HD, regenerative medicine may offer new thera-
peutic approaches for treating the disease. While preliminary
clinical trials using fetal neural grafts showed modest success
(Bachoud-Le´vi et al., 2006; Dunnett and Rosser, 2004), recent
studies have looked to build upon progress in the human
stem cell field to explore a potentially more expandable and
adaptable source of cells for transplantation therapy (Dey
et al., 2010; Schwarz and Schwarz, 2010; Snyder et al., 2010;
Vazey et al., 2010).CThe recent landmark discovery that somatic cells can be re-
programmed into induced pluripotent stem cells (iPSCs) (Okita
et al., 2007) sparked a confluence of studies to understand their
growth and manipulation, as well as their potential use in
regenerative medicine (Brennand et al., 2011; Park et al.,
2008; Wu and Hochedlinger, 2011). In devastating neurological
diseases such as HD, Parkinson’s disease (PD), and amyotro-
phic lateral sclerosis (ALS), and in stroke and spinal cord injury,
it is the loss of neurons and the inability to efficiently mobilize
inherent regenerative mechanisms to recover from the acute
or progressive damage that underlies the pathology and prog-
nosis. As such, stem-cell-based therapies hold promise for the
future treatment of these diseases where currently no disease-
modifying therapy exists. Complimentary to stem cell replace-
ment therapies is the study of human stem cells as disease
models to identify novel drugs by providing a platform for a
better understanding of these diseases at the molecular and
cellular level (Ku et al., 2010; Ruby and Zheng, 2009). In
accord with this goal, we recently described an HD-iPSC-
derived neural stem cell (NSC) model to understand disease
pathogenesis and screen for drugs in HD research (Zhang
et al., 2010).
The ability to genetically modify human stem cells is an invalu-
able approach for both modeling diseases and providing poten-
tial therapies. Gene targeting by homologous recombination is
one feasible and surgically targeted modification that holds
promise for providing normal cells that can be used to treat
genetic diseases such as HD. Such methods have been well
developed into highly optimized protocols for the genetic
manipulation of mouse embryonic stem cells (ESCs). Yet due
to a variety of technical challenges posed by human stem cell
manipulation, gene targeting in human ESCs and iPSCs has
not been as well established (Costa et al., 2007; Davis et al.,
2009; Ruby and Zheng, 2009; Song et al., 2010; Urbach et al.,
2004; Yusa et al., 2011; Zou et al., 2009; Zwaka and Thomson,
2003). Thus, gene targeting protocols in human pluripotent
stem cells are still in their infancy, and require further develop-
ment to establish their feasibility as tools for regenerative
medicine.
As a critical step in advancing gene targeting strategies for the
correction of disease mutations, we established methods to
perform genetic correction in iPSCs derived from an HD patient.
We obtained a line of HD-patient-derived iPSCs (HD-iPSC)
established and characterized by G.Q. Daley’s group (Park
et al., 2008) and us (Zhang et al., 2010). The results of our study
are described below.ell Stem Cell 11, 253–263, August 3, 2012 ª2012 Elsevier Inc. 253
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Targeted Correction of the Expanded HTT Gene in HD-
iPSCs
To achieve successful gene targeting in HD-iPSCs, we devel-
oped efficient and reproducible methods for transfection and
stable selection of human ESCs and iPSCs. We optimized a nu-
cleofection-based protocol adapted to single-cell dissociated
feeder free cultures of iPSCs to achieve maximal transfection
efficiency and cell viability (Song et al., 2010; Zou et al., 2009;
Zwaka and Thomson, 2003). In human cells, lower targeting effi-
ciencies have led several groups to employ longer homologous
arms (5–100 kb) with marked increases in efficiency reported
(Frendewey et al., 2010; Song et al., 2010). Therefore we engi-
neered longer homologous arms from a bacterial artificial
chromosome (BAC) clone containing the entire HTT gene with
normal CAG length (21 CAG). The targeting vector (Figure 1A)
comprises a 4.5 kb short arm and a 10 kb long arm flanking
the CAG repeat region plus a 1.5 kb upstream sequence of
Htt. A removable cassette that contains a PGK-neo and the
CMV-EGFP is incorporated at the 50 end of the upstream
sequence. Thus, the span of DNA that is targeted and replaced
includes exon 1, the CAG repeat region, and the 1.5 kb of
upstream sequence. The effective changes to the final targeted
allele amount to the CAG repeat length, and insertion of the
removable neomycin and EGFP cassette upstream of the re-
ported promoter region.
HD-iPSCs (Park et al., 2008) were nucleofected with both
the targeting construct and pEGFP controls. These iPSCs were
reprogrammed from HD patient fibroblast cells in which the
expanded allele CAG repeat length is 72. EGFP-expressing cells
are visible 1 day after nucleofection (Figure 1B). After a period of
2–3 weeks with selection on conditioned medium containing
50 mg/ml G418, discrete colonies were manually passaged into
individual wells for expansion and screening.
In order to reduce the large screening population, we first
designed a primary screen amplifying the CAG repeat region of
the Htt gene. This screen was intended not as proof of gene
targeting, but as a step by which we could reduce the screening
pool for Southern analysis. Clones were determined to be
targeted candidates if the PCR showed amplification of the
normal allele in the absence of the expanded allele product (Fig-
ure 1C). While this screen does not exclude false positives suchFigure 1. Targeted Correction of the Expanded Allele in HD-iPSCs
(A) Exon 1 (e1) and surrounding regions of the expanded HD locus of patient-de
vector from BACRP11-866L6 with short and long arms of 4.5 and 10 kb respective
FLP flanked PGK-neo and EGFP cassettes inserted upstream of the reported pr
300 bp external Southern probe (black bar) are shown.
(B) Brightfield (BF) and GFP fluorescent images of HD-iPSCs nucleofected with p
(C) Primary PCR-based screen of G418 resistant clones for loss of the expand
Southern blot as correctly targeted alleles.
(D) Southern blotting analysis of HindIII digested HD-iPSC clone genomic DNA a
a 10 kb nontargeted (WT) or 5 kb targeted HindIII. Labeled are positive and negativ
Rec, respectively); nontargeted HD-iPSC clones C99 and C112; and correctly ta
sequencing of clones, see Figure S1.
(E) Expanded polyglutamine correction revealed by western blot analysis of lysa
huntingtin (Htt2166) and expanded polyglutamine (1C2). A line of normal iPSC
a wild-type allele control.
(F) Summary of the gene targeting experiment and resulting targeting frequencie
Cas nonspecific contraction, deletions, or PCR-based artifacts, it
reduced our screening population to 6% of the original pool (Fig-
ure 1F). Candidate alleles were then screened using classic
Southern blot analysis. A 300 bp probe external to the 50 short
arm hybridizes to a 10 kb HindIII fragment generated by a non-
targeted allele, while a targeted recombination introduces
a HindIII site 1.5 kb upstream of exon 1, resulting in a 5 kb HindIII
fragment (Figures 1A and 1D). Clones that were shown by
Southern blot analysis to be correctly targeted were verified
again with independent genomic DNA preparations. In addition,
a second Southern blot using an internal neomycin probe was
performed to confirm the absence of other off-target integrants
(Figure S1A available online). Among 203 clones screened, 12
clones were found to be CAG positive, and 2 (c-HD-iPSC-clone
C127 and c-HD-iPSC-clone C116) of the 12 clones were further
verified by Southern blot analysis to be correctly targeted (Fig-
ure 1D), roughly 1% of the colonies screened (Figure 1F). This
rate of recombination is consistent with previous reports of
homologous recombination in human ESCs (Costa et al., 2007;
Sakurai et al., 2010; Zwaka and Thomson, 2003). Sequencing
of exon 1 region was performed to determine CAG repeat
lengths. The original HD-iPSC line sequenced has two alleles
of 73 and 19 CAG repeats, while corrected lines C116 and
C127 have sequences with 21 CAG repeats for C116 and 20
CAG repeats for C127 (Figure S1B).
Western blots of iPSCs derived from controls without disease
(normal iPSCs), HD-iPSCs, c-HD-iPSC-clone C127, and c-HD-
iPSC-clone C116 confirm the concordant loss of expanded-
length Htt protein (Figure 1E). This is shown by the separation
of mutant Htt from the wild-type Htt in the western blot
(lane 2), as detected by Htt antibody 2166 (which recognizes
both expanded and nonexpanded protein) and by the use of
disease-specific antibody 1C2 (which recognizes the expanded
polyglutamine stretch). As expected, both corrected (C116 and
C127) and normal iPSCs express only the wild-type Htt protein.
Corrected HD-iPSCs Retain Pluripotent Characteristics
Next, we investigated whether the corrected HD-iPSCs main-
tained the pluripotent characteristics of the original HD-iPSC
clone. The original HD-iPSC clone had been well characterized
with a variety of assays for pluripotency (Park et al., 2008). In
further characterizing the corrected HD-iPSCs, we chose to
apply several widely accepted assays in order to evaluaterived HD-iPSCs containing 72 polyglutamine repeats; the designed targeting
ly; and the resulting correctly targeted allele with 21 polyglutamine repeats and
omoter region. HindIII sites (H) and resulting targeted fragment sizes using the
EGFP plasmid at 1 day postnucleofection and after 3 weeks of G418 selection.
ed (72 CAG) allele. Targeted clones indicated in green were later verified by
nd control samples. A P32 radiolabeled 300 bp external probe hybridizes with
e BAC DNA controls for cassette insertion or noninsertion (BAC Rec+ and BAC
rgeted HD-iPSC clones C127 and C116. For further Southern blot analysis and
tes from HD-iPSCs and corrected clones C116 and C127 using antibodies for
s (Park et al., 2008) derived from non-HD patient fibrobasts is included as
s observed.
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Figure 2. Characterization of Corrected HD-iPSC Clones
(A) Corrected HD-iPSC line C127 immunostained for stem cell markers (Oct4, Sox2, Nanog, SSEA4, and TRA-1-60), costained with DAPI.
(B) Immunostaining of C127-derived embryoid bodies shows differentiation into ectoderm (Nestin), mesoderm (smooth muscle actin, SMA), and endoderm
(Sox17) fates.
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staining for a panel of stem cell markers showed uniform ex-
pression of these classical pluripotency markers, including
Nanog, Sox2, Oct4, SSEA4, and TRA-1-60 (Figure 2A). Further,
immunostaining of attached embryoid bodies (EBs) derived
from these clones showed cells differentiated into endoderm,
ectoderm, and mesoderm layers (Figure 2B). Karyotyping and
G-banding analysis of both clones were performed to confirm
the absence of chromosomal abnormalities (Figure 2C).
To establish that the genetically corrected HD-iPSCs were
similar to our starting cells, we performed gene expression
profiling (Figure 2D, accession number GSE37547). Strikingly,
we found very few changes in mRNA expression levels in our
genetically corrected HD-iPSCs when compared to the starting
HD-iPSCs, suggesting that theymaintained their original pluripo-
tency and that the transfection process did not cause gross
alterations in gene expression. The two groups do not separately
cluster as demonstrated by hierarchical clustering and principal
component analysis of the corrected HD-iPSCs and the starting
HD-iPSCs (Figures S2A and S2B).
Htt CAG Contraction Corrects Cadherin
and TGF-b Signaling Pathways
However, when we compared the corrected HD-iPSC group
(n = 8) versus the starting HD-iPSC group (n = 8) for significant
differential gene expression using a t test with a false discovery
rate of 5% (Benjamini-Hochberg), we detected 259 differentially
expressed genes (Table S1). These results suggest that any
changes we observe are due to the CAG contraction because
these cells have an identical genetic background. Pathway
analysis of the genes that were changed suggested that
cadherin family, TGF-b, andcaspase-related signalingmolecules
were altered in the nonexpanded iPSCs (Figure 2E). More
specifically, we detected that the Interpro protein domains
‘‘IPR013164:Cadherin, N-terminal,’’ ‘‘IPR002126:Cadherin,’’
and ‘‘IPR002190:MAGE protein’’ were overrepresented in genes
that have a lower expression level in the HD-iPSCs, and that the
KEGG pathway ‘‘hsa04350:TGF-beta signaling pathway’’ and
Reactome pathway ‘‘REACT_604:Hemostasis’’ were statistically
enriched in genes with a higher expression level in HD-iPSCs.
These pathways are altered in HD models and postmortem
tissue (Battaglia et al., 2011; Kandasamy et al., 2010; Reis
et al., 2011). Further, reverse transcriptional quantitative PCR
(RT-qPCR) analysis was used to verify the gene expression
change on these targets using independent samples from HD-
iPSCs, corrected HD-iPSCs (C116 and C127), and normal iPSCs
(Figure 2F). When comparing corrected HD-iPSCs and normal
iPSCs to HD-iPSCs, the RT-qPCR showed upregulation of cad-
herin family genes, including protocadherin 11 (PCDH11), pro-
tocadherin beta 13 (PCDHB13), and protocadherin gamma
subfamily A10 andA2 (PCDHGA10 andPCDHGA2), anddownre-(C) Karyotyping and G-banding analysis confirms the absence of genetic abnorm
(D) Genes altered as a function of genetic correction in the CAG locus of HTT in
(E) Gene array analysis indicates that the corrected clones remain similar to the
expression profile of the cells. See Figure S2 and Table S1 for microarray analys
(F) RT-qPCR verification of altered pathways in uncorrected HD-iPSCs compare
from HD-iPSCs, normal iPSCs, and two lines of corrected HD-iPSCs. RT-qPC
regulation of TGF-b pathway genes. One-way ANOVA is used for statistical anal
Cgulation of TGF-b pathway genes, including cyclin-dependent
kinase inhibitor 2B (CDKN2B), inhibitor of DNA binding 2 (ID2),
inhibitor of DNA binding 4 (ID4), paired-like homeodomain tran-
scription factor 2 (PITX2), thrombospondin 1 (THBS1), and left-
right determination factor 2 (LEFTY2).
It should be noted that when we used gene array analysis to
compare iPSCs from normal individuals to either HD-iPSCs or
corrected iPSC lines, we found that the number of differentially
expressed genes differed by an order of magnitude more over
the number resulting from the comparison of the isogenic HD-
iPSCs and the corrected iPSC pair (data not shown). Thus, while
correction of the Htt expansion may confer an allelic similarity to
a normal cell line in terms of the Htt locus, it is clear that cell lines
derived from normal but genetically diverse individuals are an
inappropriate point of reference.
Reversal of HD Phenotype in Genetically Corrected
HD-NSCs
We sought to establish whether genetic correction results in the
reversal of previously established HD disease phenotypes. In
other words, are we correcting both the genetic mutation and
the phenotype causing the disease? This of course is particularly
important if these cells are going to be eventually utilized in
patient-based stem cell therapies.
Given that targeted correction of the HTT gene results in an
isogenic background between the HD-iPSC and corrected
iPSC lines, it is not surprising to find that correction of the ex-
panded allele results in very few changes in expression at the
undifferentiated iPSC state. Consistent with this, we observed
that corrected iPSCs showed no significant changes in prolifer-
ation when compared to HD-iPSCs (Figures S3A and S3B).
Therefore, we investigated the phenotype of NSCs derived
from HD-iPSCs, corrected HD-iPSCs, and iPSCs derived from
healthy individuals. One of the hallmarks of HD is massive cell
death found in the striatum and cortex. Therefore, using the
TUNEL assay, we tested whether, under growth factor with-
drawal, the NSCs derived from HD patients were more vulner-
able to cell death than the corrected NSCs or normal NSCs.
We found that NSCs derived from uncorrected HD-iPSCs (HD-
NSCs) had an 2-fold increase in TUNEL-positive cells when
compared to normal NSCs or NSCs from two corrected HD-
iPSC lines (C116-NSCs and C127-NSCs) (Figures 3A and 3B).
We previously found that HD-iPSC-derived NSCs had
increased caspase activity compared with NSCs derived from
either iPSCs without a CAG expansion or H9 ESCs (Park et al.,
2008; Zhang et al., 2010). Elevated caspase activity upon stress
has been observed in HD models and patients (Hermel et al.,
2004; Kiechle et al., 2002; Squitieri et al., 2011). Therefore, we
hypothesized that genetic correction of the CAG repeat in the
HD-iPSC should normalize this pathway and HD-associated
phenotypes. We tested the NSCs derived from uncorrectedalities in one line (C127) of corrected HD-iPSC clones.
pathways and domain interactions.
HD-iPSC clones, suggesting that the genetic correction did not alter the gene
is.
d with corrected HD-iPSCs and normal iPSCs. RNA samples were harvested
R was performed to show upregulation of cadherin family genes and down-
ysis (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 3. Corrected HD-iPSC NSCs Have a Phenotype Similar to That of Normal iPSC NSCs
(A and B) TUNEL staining and quantification of NSCs derived from uncorrected HD-iPSCs (HD-NSCs), two lines of corrected HD-iPSCs (C116-NSCs and
C127-NSCs), and healthy iPSCs (normal NSCs).
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with normal repeat length for caspase-3/7 activity after growth
factor deprivation. Indeed, we found that only HD-NSCs showed
a significant increase in caspase-3/7 activity upon growth factor
deprivation. In contrast, the two groups of corrected NSCs
(C116-NSCs andC127-NSCs), aswell as NSCs bearing a normal
repeat length, did not show an increase in caspase-3/7 activity
upon growth factor withdrawal (Figure 3C). We also tested for
caspase-3/7 activity in uncorrected and corrected HD-iPSCs
(clone 116 and clone 127) after serum/growth factor withdrawal.
Similarly to the proliferation experiments, we found no difference
in measured change of caspase-3/7 activity upon growth factor/
serumwithdrawal in the undifferentiated iPSC state (Figure S3C).
Interestingly the difference between iPSC and NSC results sug-
gests that polyglutamine expansionmakes cells more vulnerable
to cell death only after differentiation. This may be relate to Htt’s
function in neural development where loss of Htt results in dis-
turbed cell migration, reduced proliferation, and increased cell
death (Tong et al., 2011).
The observed susceptibility to growth factor withdrawal in
HD-NSCs may correlate with the well-documented alteration in
BDNF levels in HD patients and models of HD (Zuccato et al.,
2001; Zuccato et al., 2008). Strikingly, we found that the genetic
correction of the CAG expansion in HD-iPSCs (C116 and C127)
corrected the altered BDNF levels found in NSCs derived from
these cells (Figure 3D).
Another phenotypic difference between HD and normal cells is
reduced bioenergetics ofmitochondria in HD (Mochel andHaller,
2011). We investigated a key bioenergetic property, oxygen
consumption rate (OCR), in uncorrected and corrected NSCs.
The XF24 extracellular flux analyzer (Seahorse Biosciences)
measured OCR in real time and we were able to compare uncor-
rected, corrected, and normal NSCs for respiratory rate. We
found that maximum respiration (average OCR after addition of
FCCP, an uncoupler) was higher in corrected NSCs or normal
NSCs as compared with uncorrected HD-NSCs (Figure 3E), sug-
gesting that genetic correction of CAG repeat resulted in
enhanced maximum respiration and mitochondrial function in
NSCs. The OCR changes in response to sequentially added
oligomycin, FCCP, and rotenone/antimycin A are indicative of
the appropriate response in this assay (Figure S3D).
Our gene array analysis pointed out altered expression of
genes belonging to cadherin and TGF-b signaling pathways in
uncorrected HD-iPSCs compared with corrected or normal
iPSC cells (Figure 2F). Previous work has also demonstrated
altered cadherin and TGF-b signaling in cellular and mouse
models of HD (Battaglia et al., 2011; Kandasamy et al., 2010;
Reis et al., 2011). Therefore, we investigated whether these
signaling pathways were altered in NSCs.We found that the level(C) NSCs derived from uncorrected HD-iPSCs showed an elevated caspase-3/7 a
factors; –GF, growth factor deprived condition. We did not detect phenotypes in
(D) NSCs from corrected and uncorrected HD-iPSCs show that BDNF levels in c
(E) NSCs derived from corrected cells show higher maximum respiration capacit
XF24 Extracellular Flux Analyzer for oxygen consumption rate (OCR). The averag
respiration capacity. Corrected NSCs and normal NSCs showed higher maximu
(F) RT-qPCR of TGF-b1 showed a decreased level of TGF-b1 mRNA in HD-NSC
(G and H) RT-qPCR and western blotting of N-cadherin showed a decreased leve
and normal NSCs.
One-way ANOVA is used for statistical analysis (*p < 0.05, **p < 0.01, ***p < 0.00
Cof TGF-b1 mRNA was lower in the HD-NSCs compared with that
in normal NSCs or corrected NSCs (C116-NSCs or C127-NSCs)
(Figure 3F). We also found that mRNA and protein levels of
N-cadherin were lower in the HD-NSCs compared with those
of normal NSCs or corrected NSCs (Figures 3G and 3H).
Striatal Differentiation of Corrected HD-iPSCs In Vitro
and In Vivo
Using the differentiation protocol we previously described
(Zhang et al., 2010) with slight modifications, we were able to
direct the corrected HD-iPSCs along the differentiation pathway
into NSCs, as shown by immunocytochemical staining of the
NSC-specific markers Nestin (Figure 4A) and Sox1 (Figure S4A).
Then these NSCs were further induced into striatal neurons,
as shown by the expression of DARPP-32, calbindin, and
gamma-aminobutyric acid (GABA) (Figures 4B and 4C).
Next the ability of corrected iPSC-derived NSCs to populate
the striatum was assessed given recent stem cell replacement
studies with human ESCs supporting functional recovery in
a quinolinic acid model of HD (Ma et al., 2012). NSCs derived
from corrected iPSCs were transplanted into the striatum of
HDmousemodel R6/2 brains at 6 weeks of age. Twoweeks after
injection, brain sections were stained for markers specific
for human cytoplasmic protein (STEM121) or human nuclear
antigen (HuNu). Confocal imaging reveals an abundant number
of STEM121-positive cells in the striatum of these mice (Fig-
ure 4D), suggesting that the corrected NSC survived transplan-
tation. Further, we found human cells colabeled with neuronal
marker MAP2 (Figures 4E–4G), medium spiny neuron marker
DARPP-32 (Figures 4J and 4K), and GABAergic neuron marker
GABA (Figures 4H and 4I). We also found glial-specific
marker GFAP (Figure 4L) colabeled with STEM121, although at
a lower percentage. Individual panels of the staining are shown
in Figure S4B. These results suggest that corrected HD-iPSC-
derived NSCs are able to populate the striatum of HD mouse
model brains and undergo differentiation in vivo to DARPP-32-
expressing neurons and glial cells.
DISCUSSION
The recent rapid progress in the advancement of reprogramming
technology facilitating the more efficient and accessible genera-
tion of patient-specific iPSCs has opened the door to the devel-
opment of strategies for iPSC-based disease modeling and
regenerative therapy (Ye et al., 2009; Yu et al., 2007; Zou et al.,
2009). In this study, we have demonstrated the use of gene
targeting techniques to achieve a targeted correction of the
expanded Htt allele in iPSCs derived from an HD patient.
Targeted correction by our strategy results in the reduction ofctivity upon growth factor withdrawl. +GF, normal culture condition with growth
iPSCs; see Figure S3.
orrected NSCs are consistent with those of a normal phenotype.
y than NSCs from uncorrected HD-iPSCs. Cells were analyzed on a Seahorse
e OCR after addition of FCCP (an uncoupler) reflects mitochondria maximum
m respiration capacity than uncorrected HD-NSCs. Also see Figure S3D.
s compared with that in corrected and normal NSCs.
l of N-cadherin mRNA and protein in HD-NSCs compared with that in corrected
1).
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Figure 4. Directed Differentiation of Corrected HD-iPSC Clones
(A) NSCs were derived from corrected HD-iPSCs with the EB method and were stained for the NSC marker Nestin.
(B) NSCs were further induced to striatal neurons with expression of DARPP-32 and bIII-tubulin.
(C) Calbindin and GABA is shown by ICC staining.
(D) Two weeks after striatal injection of corrected NSCs (C116-NSCs), immunofluorescence of R6/2 mouse brain sections detects human-specific STEM121
and DAPI.
(E–G) STEM121 and MAP2 R6/2 mouse brain sections counterstained with DAPI.
(H and I) STEM121 and GABA R6/2 mouse brain sections counterstained with DAPI.
(J and K) STEM121 and DARPP-32 R6/2 mouse brain sections counterstained with DAPI.
(L) STEM121 and GFAP R6/2 mouse brain sections counterstained with DAPI.
For further analysis see Figure S4.
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repeats, while maintaining the pluripotent characteristics and
unique gene profile of the original patient-specific iPSC line.
We further demonstrate the ability for these corrected iPSCs to
undergo directed differentiation into DARPP-32-positive striatal
neurons in vitro and in vivo. Most significantly, we show that
correction results in reversal of disease phenotype in NSCs
derived from the corrected HD-iPSCs.
Despite recent success in using zinc-finger nuclease (ZFN)-
mediated gene targeting (Hockemeyer et al., 2009; Zou et al.,
2009), we chose not to pursue this strategy due to the time
and resources required for experimentally optimizing the binding
specificity of zinc-finger motifs, and, particularly relevant to CAG
mutations, we wanted to avoid ‘‘off-target’’ effects. Our positive
results further indicated that targeting frequencies as observed
here and previously reported are within the reasonable range
of achievability, given efficient protocols and a well designed
targeting strategy. In the context of regenerative therapeutics,
removal of cassette DNA containing selection markers would
be a clear requirement, and as such, we designed our vectors
with this capability in mind, and they can be utilized with multiple
patient iPSCs.
With the inherent limitations of previous clinical xenograft
transplantation approaches, which are prone to immunorejec-
tion and limited tissue supply, focus has shifted to stem-cell-
based sources for transplantation (Dunnett and Rosser, 2004;
Kelly et al., 2009). The ability to combine genetic manipulation
technology with disease-specific iPSCs creates the potential
for generation of autologous cells for cell-replacement therapy.
While gene targeting approaches have been demonstrated
previously in iPSCs, our current study provides an important
proof of principle experiment demonstrating the genetic correc-
tion of the HD-causing mutation in patient-derived iPSCs. It is of
particular significance that we find that genetic correction
reverses disease phenotypes in these cells. Further, we provide
evidence for the capability of these cells to populate and differ-
entiate in the diseased striatum in vivo, which complements
recent studies showing functional rescue in a quinolinic acid
model of HD (Ma et al., 2012). As such these findings represent
a significant contribution to ongoing efforts and future studies
aiming to harness the potential of iPSCs for regenerative
therapy.
Much focus has been invested on the use of disease-specific
iPSCs to develop in vitro cell models for the study of disease
pathway mechanisms and, in some cases, toward a platform
for drug screening and discovery. In our study, an important
goal was the creation of genetically corrected HD-iPSCs, which
provides us with a human HD model in which the normal and
disease cell lines carry identical genetic backgrounds with
respect to each other. Gene-corrected iPSCs may serve as
a more closely matched control for the study of HD-mediated
gene changes because they are derived from the same patient
and thus have a matched genetic background. With this in
mind, we performed a preliminary analysis of gene expression
differences between HD and corrected iPSCs, which revealed
changes to cadherin family genes and TGF-b signaling path-
ways. Adding further utility is the ability to direct the differen-
tiation of these HD and corrected iPSCs into NSCs and
DARPP-32-positive striatal neurons.CIn summary, we found that we could correct phenotypes asso-
ciated with HD using homologous recombination at frequencies
of homologous recombination comparable to those in previous
reports (Costa et al., 2007; Song et al., 2010; Zwaka and Thom-
son, 2003). The corrected cells retain pluripotent characteristics,
as monitored by ICC and microarray analysis, and could be
differentiated into DARPP-32-expressing striatal neurons. One
could easily have hypothesized that, due to epigenetic alter-
ations in the diseased cells caused by genetic mutation and
aging, the disease process could not be reversed. However,
we found that the replacement of the disease gene mutation
reversed the phenotype of the diseased cells. The observed
elevation of capase-3/7 activity in HD NSCs upon growth factor
deprivation recapitulates a well-characterized disease pheno-
type observed in various rodent and human HD models, and
correction of the genetic mutation reversed this phenotype.
Further, we found that the altered mitochondrial deficits, the
lower levels of BDNF, and the altered cadherin and TGF-b
signaling associated with HD were corrected. The NSCs derived
from these corrected cells could populate the striatum in an HD
mouse model. Our results are a significant advance in working
with HD-iPSCs for stem cell replacement therapy and construct-
ing human HD cellular models with the same human genetic
background.
EXPERIMENTAL PROCEDURES
Construction of Targeting Vector
A 240 kb BAC (RP11-866L6) containing the 170 kb human HTT locus was
modified stepwise using a Ret/ET-based recombineering kit (Genebridges).
First, PGK-neo and CMV-EGFP expression cassettes flanked by FRT re-
cognition sites was inserted 1.5 kb upstream of exon 1. The 20 kb fragment,
including exon 1, inserted expression cassettes, a 4.5 kb upstream short
arm, and a 10 kb downstream long arm, were inserted into a modified pPNT
vector (neo cassette removed) adjacent to the HSV-TK.
Culture and Nucleofection of HD-iPSCs
Cell culture reagents were from Invitrogen unless otherwise mentioned. HD-
iPSC (HD-iPS4) and normal iPSCs (hFib2-iPS5) (Park et al., 2008)were cultured
on either Matrigel (BD) or irradiation inactivated mouse embryonic fibroblasts
(MEFs). Further details are in the Supplemental Experimental Procedures.
Karyotyping Analysis and Sequencing
Karyotyping of the targeted iPSC was carried out by Applied Stemcell Inc.
(Menlo Park, CA). Sequencing was performed by Laragen. Multiple primer
sets were used to amplify the exon 1 region of the HTT gene. For each clone,
the twoCAG length allele variants were gel isolated and sequenced separately.
Immunocytochemical Staining
Cells grown on coverslips were fixed with 4% paraformaldehyde (Sigma) for
20 min at room temperature (RT), then permeabilized with 0.1% Triton X-100
(Sigma) for 10 min and blocked with 5% donkey serum (Millipore) for 45 min.
See Supplemental Experimental Procedures.
Neuronal Differentiation of HD-iPSCs
NSCs were derived from iPSCs with the EB method as previously published
and with some modifications. Normal NSCs (HIP Neural Stem Cells) derived
from healthy iPSCs using a similar EB method were from GlobalStem. See
Supplemental Experimental Procedures.
Western Blotting Analysis
HD-iPSCs, normal iPSCs, and corrected HD-iPSCs were detached by
1mg/ml collagenase (Invitrogen) incubation at 37C for 1 hr. See Supplemental
Experimental Procedures.ell Stem Cell 11, 253–263, August 3, 2012 ª2012 Elsevier Inc. 261
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RNA was extracted from pellets of cell cultures using an automated
homogenization and extraction apparatus (QiaCube, QIAGEN, Valencia, CA)
according to the manufacturer’s protocols for the RNeasy mini kit (QIAGEN).
See Supplemental Experimental Procedures.
Caspase-3/7 Activity Assay
The caspase activity assay was performed with Apo3 HTS kit (Cell
Technology).
NSC Injection and Analysis
105 corrected NSCs (C116) were injected bilaterally into the striatum of
6-week-old R6/2 transgenic HD model mice (via the following stereotaxic
coordinates: bregma +0.86 AP, ±1.8 ML, and at –3.5, 2.5 DV depths) in
a 1 ml volume using a 22G Hamilton syringe. Mice were transcardially perfused
with 4% paraformaldehyde at 2 weeks postinjection, brains were processed in
a sucrose gradient (10%–30%), and coronal sections (30 mm thick) through the
striatum were serially collected. Injected cells were visualized by confocal
imaging after immunostaining with human-specific nuclear antigen (1:100,
clone 235-1, Millipore) or STEM121 (1:100, Stem Cells Inc.). Colabeling with
other neuronal and glial markers was done with antibodies against DARPP-
32 (1:20, Cell Signaling), MAP2 (1:100, Millipore), GABA (1:100, Abcam or
Millipore), and GFAP (1:100, Sigma).
Statistical Analysis
For all comparisons we used one-way ANOVA analysis. For microarray and
enrichment, statistical analysis is noted in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The accession number for the microarray data gathered in the course of this
experiment is GSE37547.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes four figures, Supplemental
Experimental Procedures, and one table and can be found with this article
online at doi:10.1016/j.stem.2012.04.026.
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